TREM-1 as a potential therapeutic target in psoriasis

Journal of Investigative Dermatology

Volumn 133, Issue 7, 2013, Pages 1742-1751

  Hyder, Luke A ^a   Gonzalez, Juana ^a   Harden, Jamie L ^a   Johnson Huang, Leanne M ^a   Zaba, Lisa C ^a   Pierson, Katherine C ^a   Eungdamrong, Narat J ^a   Lentini, Tim ^a   Gulati, Nicholas ^a   Fuentes Duculan, Judilyn ^a   Suárez Fariñas, Mayte ^a   Lowes, Michelle A ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; ETANERCEPT; INTERLEUKIN 8; IXEKIZUMAB; MONOCYTE CHEMOTACTIC PROTEIN; PEPTIDOGLYCAN; PLACEBO; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR;

ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MONOCYTE; MYELOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PSORIASIS; TH17 CELL; ULTRAVIOLET B RADIATION;

EID: 84879419176     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.68     Document Type: Article

References (36)

1. Amatngalim GD, Nijnik A, Hiemstra PS et al. (2011) Cathelicidin peptide LL-37 modulates TREM-1 expression and inflammatory responses to micro-bial compounds. Inflammation 34:412-25
2. Bleharski JR, Kiessler V, Buonsanti C et al. (2003) A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response. J Immunol 170:3812-8 (Pubitemid 36359251)
3. Bouchon A, Dietrich J, Colonna M (2000) Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 164:4991-5 (Pubitemid 30305166)
4. Bouchon A, Facchetti F, Weigand MA et al. (2001) TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 410:1103-7 (Pubitemid 32391042)
5. Chen LC, Laskin JD, Gordon MK et al. (2008) Regulation of TREM expression in hepatic macrophages and endothelial cells during acute endotoxemia. Exper Mol Pathol 84:145-55
6. Cheong C, Matos I, Choi JH et al. (2010) Microbial stimulation fully differentiates monocytes to DC-SIGN/CD209(+) dendritic cells for immune T cell areas. Cell 143:416-29
7. Ford JW, McVicar DW (2009) TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 21:38-46
8. Fuentes-Duculan J, Suárez-Fariñas M, Zaba LC et al. (2010) A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol 130:2412-22
9. Funderburg N, Lederman MM, Feng Z et al. (2007) Human-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA 104:18631-5 (Pubitemid 350210748)
10. Gibot S, Kolopp-Sarda MN, Bene MC et al. (2004) A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exper Med 200: 1419-26 (Pubitemid 39657289)
11. Ingersoll MA, Platt AM, Potteaux S et al. (2011) Monocyte trafficking in acute and chronic inflammation. Trends Immunol 32:470-7
12. Jabbari A, Suarez-Farinas M, Dewell S et al. (2012) Transcriptional profiling of psoriasis using RNA-seq reveals previously unidentified differentially expressed genes. J Invest Dermatol 132:246-9
13. Johnson-Huang LM, Suarez-Farinas M, Sullivan-Whalen M et al. (2010) Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol 130:2654-63
14. Jordan CT, Cao L, Roberson ED et al. (2012a) Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet 90:796-808
15. Jordan CT, Cao L, Roberson ED et al. (2012b) PSORS2 is due to mutations in CARD14. Am J Hum Genet 90:784-95
16. Kennedy-Crispin M, Fuentes-Duculan J, Gulati N et al. (2012) Gene profiling of narrow-band UVB-induced skin injury defines cellular and molecular innate immune responses. J Invest Dermatol 133:692-701
17. Krueger JG, Fretzin S, Suárez-Fariñas M et al. (2012) IL-17A is essential for cell activation and inflammatory gene circuits in psoriasis. J Allerg Clin Immunol 130:145-54
18. Lin AM, Rubin CJ, Khandpur R et al. (2011) Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 187:490-500
19. Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of psoriasis. Nature 445:866-73
20. Lowes MA, Chamian F, Abello MV et al. (2005) Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 102:19057-62 (Pubitemid 43049565)
21. Matesanz-Isabel J, Sintes J, Llinas L et al. (2011) New B-cell CD molecules. Immunol Lett 134:104-2
22. Park JJ, Cheon JH, Kim BY et al. (2009) Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. Digest Dis Sci 54:1525-31
23. Rigo I, McMahon L, Dhawan P et al. (2012) Induction of triggering receptor expressed on myeloid cells (TREM-1) in airway epithelial cells by 1, 25(OH)(2) vitamin D(3). Innate Immun 18:250-7
24. Schenk M, Bouchon A, Seibold F et al. (2007) TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest 117:3097-106 (Pubitemid 47529639)
25. Serbina NV, Kuziel W, Flavell R et al. (2003a) Sequential MyD88-independent and-dependent activation of innate immune responses to intracellular bacterial infection. Immunity 19:891-901 (Pubitemid 37542308)
26. Serbina NV, Salazar-Mather TP, Biron CA et al. (2003b) TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19:59-70 (Pubitemid 36859901)
27. Suárez-Fariñas M, Fuentes-Duculan J, Lowes MA et al. (2010) Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol 131:391-400
28. Tessarz AS, Cerwenka A (2008) The TREM-1/DAP12 pathway. Immunol Lett 116:111-6
29. Tian S, Krueger JG, Li K et al. (2012) Meta-analysis derived (MAD) transcrip-tome of psoriasis defines the "core" pathogenesis of disease. PLoS One 7:e44274
30. Wang F, Lee E, Lowes MA et al. (2006) Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects. J Invest Dermatol 126:1590-9
31. Wu J, Li J, Salcedo R et al. (2012) The pro-inflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocel-lular carcinoma. Cancer Res 72:3977-86
32. Zaba LC, Cardinale I, Gilleaudeau P et al. (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exper Med 204:3183-94
33. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ et al. (2009a) Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 129:79-88
34. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ et al. (2010) Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allerg Clin Immunol 125:e9
35. Zaba LC, Krueger JG, Lowes MA (2009b) Resident and ''inflammatory'' dendritic cells in human skin. J Invest Dermatol 129:302-8
36. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J et al. (2009c) Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allerg Clin Immunol 124:e1-395